Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 6 , Pages 941-953 , December 2008

Routine serum calcitonin measurement in the evaluation of thyroid nodules

References 

  1. Deftos LJ, Lee MR, Potts JT. A radioimmunoassay for thyrocalcitonin. Proceedings of the National Academy of Sciences of the United States of America. 1968;60:293–299
  2. Tashjian AH. Immunoassay of thyrocalcitonin. I. The method and its serological specificity. Endocrinology. 1969;84:140–148
  3. Przepiorka D, Baylin SB, McBride OW, et al. The human calcitonin gene is located on the short arm of chromosome 11. Biochemical and Biophysical Research Communications. 1984;120:493–499
  4. Hoppener JW, Steenbergh PH, Zandberg J, et al. The second human calcitonin/CGRP gene is located on chromosome 11. Human Genetics. 1985;70:259–263
  5. Cooper CW, Deftos LJ, Potts JT. Direct measurement of in vivo secretion of pig thyrocalcitonin by radioimmunoassay. Endocrinology. 1971;88:747–754
  6. Emmertsen KK, Nielsen HE, Mosekilde L, et al. Pentagastrin, calcium and whisky stimulated serum calcitonin in medullary carcinoma of the thyroid. Acta Radiologica. Oncology. 1980;19:85–89
  7. Vitale G, Ciccarelli A, Caraglia M, et al. Comparison of two provocative tests for calcitonin in medullary thyroid carcinoma: omeprazole vs pentagastrin. Clinical Chemistry. 2002;48:1505–1510
  8. Oishi S, Yamauchi J, Fujimoto Y, et al. Calcitonin release from medullary thyroid carcinoma by thyrotropin-releasing hormone: comparison with calcium injection. Acta Endocrinologica. 1992;126:325–328
  9. Lin HY, Harris TL, Flannery MS, et al. Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science. 1991;254:1022–1024
  10. Hoff AO, Catala-Lehnen P, Thomas PM, et al. Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. The Journal of Clinical Investigation. 2002;110:1849–1857
  11. Deftos LJ, First BP. Calcitonin as a drug. Annals of Internal Medicine. 1981;95:192–197
  12. Purdue BW, Tilakaratne N, Sexton PM. Molecular pharmacology of the calcitonin receptor. Receptors and Channels. 2002;8:243–255
  13. Raue F, Schmidt-Gayk H, Ziegler R. Tumor markers in C-cell cancer, Deutsche medizinische Wochenschrift (1946). 1983;108:283–287
  14. Bockhorn M, Frilling A, Rewerk S, et al. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. Thyroid. 2004;14:468–470
  15. Christensen SB, Ljungberg O, Tibblin S. A clinical epidemiologic study of thyroid carcinoma in Malmo, Sweden. Current Problems in Cancer. 1984;8:1–49
  16. Pacini F, Fontanelli M, Fugazzola L, et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism. 1994;78:826–829
  17. Bergholm U, Adami HO, Telenius-Berg M, et al. Incidence of sporadic and familial medullary thyroid carcinoma in Sweden 1959 through 1981. A nationwide study in 126 patients. Swedish MCT Study Group. Acta Oncologica. 1990;29:9–15
  18. Bondeson L, Ljungberg O. Occult thyroid carcinoma at autopsy in Malmo, Sweden. Cancer. 1981;47:319–323
  19. Bhattacharyya N. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngology and Head and Neck Surgery. 2003;128:115–123
  20. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–460
  21. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Molecular Genetics. 1993;2:851–856
  22. Santoro M, Carlomagno F. Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nature Clinical Practice. 2006;2:42–52
  23. Romei C, Elisei R, Pinchera A, et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. The Journal of Clinical Endocrinology and Metabolism. 1996;81:1619–1622
  24. Zedenius J, Larsson C, Bergholm U, et al. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. The Journal of Clinical Endocrinology and Metabolism. 1995;80:3088–3090
  25. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. The Journal of Clinical Endocrinology and Metabolism. 2008;93:682–687
  26. Hazard JB, Hawk WA, Crile G. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. The Journal of Clinical Endocrinology and Metabolism. 1959;19:152–161
  27. Melvin KE, Tashjian AH. The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid. Proceedings of the National Academy of Sciences of the United States of America. 1968;59:1216–1222
  28. Christensen SB, Ljungberg O. Mortality from thyroid carcinoma in Malmo, Sweden 1960–1977. A clinical and pathologic study of 38 fatal cases. Cancer. 1984;54:1629–1634
  29. Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139–1148
  30. Gharib H, McConahey WM, Tiegs RD, et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clinic proceedings. 1992;67:934–940
  31. Baloch ZW, LiVolsi VA. Fine-needle aspiration of thyroid nodules: past, present, and future. Endocrine Practice. 2004;10:234–241
  32. Soderstrom N, Telenius-Berg M, Akerman M. Diagnosis of medullary carcinoma of the thyroid by fine needle aspiration biopsy. Acta Medica Scandinavica. 1975;197:71–76
  33. Mendonca ME, Ramos S, Soares J. Medullary carcinoma of thyroid: a re-evaluation of the cytological criteria of diagnosis. Cytopathology. 1991;2:93–102
  34. Takeichi N, Ito H, Okamoto H, et al. The significance of immunochemically staining calcitonin and CEA in fine-needle aspiration biopsy materials from medullary carcinoma of the thyroid. The Japanese Journal of Surgery. 1989;19:674–678
  35. Papaparaskeva K, Nagel H, Droese M. Cytologic diagnosis of medullary carcinoma of the thyroid gland. Diagnostic Cytopathology. 2000;22:351–358
  36. Forrest CH, Frost FA, de Boer WB, et al. Medullary carcinoma of the thyroid: accuracy of diagnosis of fine-needle aspiration cytology. Cancer. 1998;84:295–302
  37. Rieu M, Lame MC, Richard A, et al. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clinical Endocrinology. 1995;42:453–460
  38. Niccoli P, Wion-Barbot N, Caron P, et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French medullary study group. The Journal of Clinical Endocrinology and Metabolism. 1997;82:338–341
  39. Vierhapper H, Raber W, Bieglmayer C, et al. Routine measurement of plasma calcitonin in nodular thyroid diseases. The Journal of Clinical Endocrinology and Metabolism. 1997;82:1589–1593
  40. Kaserer K, Scheuba C, Neuhold N, et al. C-cell hyperplasia and medullary thyroid carcinoma in patients routinely screened for serum calcitonin. The American Journal of Surgical Pathology. 1998;22:722–728
  41. Ozgen AG, Hamulu F, Bayraktar F, et al. Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid. 1999;9:579–582
  42. Hahm JR, Lee MS, Min YK, et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid. 2001;11:73–80
  43. Bugalho MJ, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. Journal of Surgical Oncology. 2005;91:56–60
  44. Kini SR, Miller JM, Hamburger JI, et al. Cytopathologic features of medullary carcinoma of the thyroid. Archives of Pathology and Laboratory Medicine. 1984;108:156–159
  45. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology / European Federation of Endocrine Societies. 2006;154:787–803
  46. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109–142
  47. Machens A, Gimm O, Ukkat J, et al. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer. 2000;88:1909–1915
  48. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. The Journal of Clinical Endocrinology and Metabolism. 2004;89:163–168
  49. Vierhapper H, Niederle B, Bieglmayer C, et al. Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid. 2005;15:1267–1272
  50. Borget I, De Pouvourville G, Schlumberger M. Editorial: Calcitonin determination in patients with nodular thyroid disease. The Journal of Clinical Endocrinology and Metabolism. 2007;92:425–427
  51. Cheung K, Roman SA, Wang TS, et al. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision Analysis. The Journal of Clinical Endocrinology and Metabolism. 2008;93:2173–2180
  52. Tsolakis AV, Portela-Gomes GM, Stridsberg M, et al. Malignant gastric ghrelinoma with hyperghrelinemia. The Journal of Clinical Endocrinology and Metabolism. 2004;89:3739–3744
  53. Niccoli P, Conte-Devolx B, Lejeune PJ, et al. Hypercalcitoninemia in conditions other than medullary cancers of the thyroid, Annales d'endocrinologie. 1996;57:15–21
  54. Samaan NA, Castillo S, Schultz PN, et al. Serum calcitonin after pentagastrin stimulation in patients with bronchogenic and breast cancer compared to that in patients with medullary thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism. 1980;51:237–241
  55. Mullerpatan PM, Joshi SR, Shah RC, et al. Calcitonin-secreting tumor of the pancreas. Digestive Surgery. 2004;21:321–324
  56. Guyetant S, Wion-Barbot N, Rousselet MC, et al. C-cell hyperplasia associated with chronic lymphocytic thyroiditis: a retrospective quantitative study of 112 cases. Human Pathology. 1994;25:514–521
  57. Albores-Saavedra J, Monforte H, Nadji M, et al. C-cell hyperplasia in thyroid tissue adjacent to follicular cell tumors. Human Pathology. 1988;19:795–799
  58. Scopsi L, Di Palma S, Ferrari C, et al. C-cell hyperplasia accompanying thyroid diseases other than medullary carcinoma: an immunocytochemical study by means of antibodies to calcitonin and somatostatin. Modern Pathology. 1991;4:297–304
  59. Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. The Journal of Clinical Endocrinology and Metabolism. 2007;92:450–455
  60. Kudo T, Miyauchi A, Ito Y, et al. Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. Thyroid. 2007;17:635–638
  61. Boi F, Maurelli I, Pinna G, et al. Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism. 2007;92:2115–2118
  62. Engelbach M, Gorges R, Forst T, et al. Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. The Journal of Clinical Endocrinology and Metabolism. 2000;85:1890–1894
  63. Tommasi M, Brocchi A, Cappellini A, et al. False serum calcitonin high levels using a non-competitive two-site IRMA. Journal of Endocrinological Investigation. 2001;24:356–360
  64. Ichimura T, Kondo S, Okushiba S, et al. A calcitonin and vasoactive intestinal peptide-producing pancreatic endocrine tumor associated with the WDHA syndrome. International Journal of Gastrointestinal Cancer. 2003;33:99–102
  65. Karanikas G, Moameni A, Poetzi C, et al. Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects. The Journal of Clinical Endocrinology and Metabolism. 2004;89:515–519
  66. Barbot N, Calmettes C, Schuffenecker I, et al. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism. 1994;78:114–120
  67. Perry A, Molberg K, Albores-Saavedra J. Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities. Cancer. 1996;77:750–756
  68. Barbot N, Guyetant S, Beldent V, et al. Chronic autoimmune thyroiditis and C-cell hyperplasia. Study of calcitonin secretion in 24 patients, Annales d'endocrinologie. 1991;52:109–112
  69. Morgan KG, Szurszewski JH. Mechanisms of phasic and tonic actions of pentagastrin on canine gastric smooth muscle. The Journal of Physiology. 1980;301:229–242
  70. Schuurkes JA, Charbon GA. Motility and hemodynamics of the canine gastrointestinal tract. Stimulation by pentagastrin, cholecystokinin and vasopressin. Archives internationales de pharmacodynamie et de therapie. 1978;236:214–227
  71. Hulstaert PF, Geurts WJ, Brouwer FA, et al. Hemodynamic actions of pentagastrin. Scandinavian Journal of Gastroenterology. 1980;15:7–15
  72. Ewers HR, Brouwers HP, Merguet P, et al. Side effects after stimulation of gastric secretion with pentagastrin (author's transl), Medizinische Klinik. 1976;71:19–23

PII: S1521-690X(08)00106-1

doi: 10.1016/j.beem.2008.09.008

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 6 , Pages 941-953 , December 2008

Article Tools

* Image Usage & Resolution